<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39334246</PMID><DateCompleted><Year>2024</Year><Month>09</Month><Day>28</Day></DateCompleted><DateRevised><Year>2024</Year><Month>09</Month><Day>30</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1741-7015</ISSN><JournalIssue CitedMedium="Internet"><Volume>22</Volume><Issue>1</Issue><PubDate><Year>2024</Year><Month>Sep</Month><Day>27</Day></PubDate></JournalIssue><Title>BMC medicine</Title><ISOAbbreviation>BMC Med</ISOAbbreviation></Journal><ArticleTitle>Post-marketing surveillance framework of cell and gene therapy products in the European Union, the United States, Japan, South Korea and China: a comparative study.</ArticleTitle><Pagination><StartPage>421</StartPage><MedlinePgn>421</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">421</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1186/s12916-024-03637-z</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Cell and gene therapy products (CGTPs) often receive accelerated approvals, lacking comprehensive long-term safety and efficacy data, which can raise significant safety concerns. This research aims to study the post-marketing surveillance (PMS) of CGTPs in the European Union (EU), the United States (US), Japan, South Korea, and China, to offer insights for the development of a secure and standardized post-marketing regulatory framework for CGTPs.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Related regulations and the implementation effect of PMS for approved CGTPs were studied searching PubMed, CNKI, and the official websites of the European Medicines Agency, the US Food and Drug Administration, Japan's Pharmaceuticals and Medical Device Agency, South Korea's Ministry of Food and Drug Safety, and the National Medical Products Administration of China.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Compared to those in China, the guidelines of PMS for CGTPs in the EU, the US, Japan, and South Korea was more comprehensive. Notably, the EU had dedicated regulations and supporting guidelines of PMS. Of the 26 CGTPs approved in the EU, 88% were under additional monitoring, 38% received conditional marketing authorization, and 12% were authorized under exceptional circumstances, with 77% designated as orphan drugs. The US had released 34 guidelines specifically for CGTPs which, forming the foundation of post-marketing risk management. Among the 27 CGTPs approved in the US, 22% were required to perform risk evaluation and mitigation strategies, 37% added black box warnings in the package inserts, 63% mandated to post-marketing requirements, and 15% subject to post-marketing commitments. In Japan, stringent supervision measures encompassing all-case surveillance (79%) and re-examination (53%) were applied to the 19 approved CGTPs, with 21% approved through conditional and time-limited approval. The PMS for CGTPs in South Korea, mainly included PSUR, re-examination, and re-evaluation. China had introduced several relevant regulations, which consisted of general statements and lacked detailed guidance.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">This study demonstrates that the regulatory policies of PMS for CGTPs in the EU, the US, Japan, and South Korea were comprehensive. The implementation of PMS for CGTPs in the EU, the US, and Japan was well developed. This knowledge holds valuable insights for China's future learning and development in this field.</AbstractText><CopyrightInformation>© 2024. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Cai</LastName><ForeName>Yuxin</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Clinical Pharmacy and Regulatory Science, School of Pharmacy, Fudan University, Shanghai, 201206, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Sui</LastName><ForeName>Lijuan</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Clinical Pharmacy and Regulatory Science, School of Pharmacy, Fudan University, Shanghai, 201206, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Wang</LastName><ForeName>Jingjing</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Rheumatology, Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, 200001, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Qian</LastName><ForeName>Weilin</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Department of Clinical Pharmacy and Regulatory Science, School of Pharmacy, Fudan University, Shanghai, 201206, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Peng</LastName><ForeName>Yeheng</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Clinical Pharmacy and Regulatory Science, School of Pharmacy, Fudan University, Shanghai, 201206, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gong</LastName><ForeName>Luyao</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Clinical Pharmacy and Regulatory Science, School of Pharmacy, Fudan University, Shanghai, 201206, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wu</LastName><ForeName>Weijia</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Center for Health Policy Studies, Zhejiang University School of Public Health, Hangzhou, 310058, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gao</LastName><ForeName>Yuan</ForeName><Initials>Y</Initials><Identifier Source="ORCID">0000-0003-3681-0411</Identifier><AffiliationInfo><Affiliation>Department of Clinical Pharmacy and Regulatory Science, School of Pharmacy, Fudan University, Shanghai, 201206, China. yuan_gao@fudan.edu.cn.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D003160">Comparative Study</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>09</Month><Day>27</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>BMC Med</MedlineTA><NlmUniqueID>101190723</NlmUniqueID><ISSNLinking>1741-7015</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D011358" MajorTopicYN="Y">Product Surveillance, Postmarketing</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002681" MajorTopicYN="N" Type="Geographic">China</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014481" MajorTopicYN="N" Type="Geographic">United States</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005062" MajorTopicYN="Y">European Union</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007564" MajorTopicYN="N" Type="Geographic">Japan</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015316" MajorTopicYN="Y">Genetic Therapy</DescriptorName><QualifierName UI="Q000331" MajorTopicYN="N">legislation &amp; jurisprudence</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D056910" MajorTopicYN="N" Type="Geographic">Republic of Korea</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D064987" MajorTopicYN="N">Cell- and Tissue-Based Therapy</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Advanced therapy medicinal products</Keyword><Keyword MajorTopicYN="N">Cell and gene therapy products</Keyword><Keyword MajorTopicYN="N">Post-marketing surveillance</Keyword><Keyword MajorTopicYN="N">Regulations</Keyword></KeywordList><CoiStatement>The authors declare that they have no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>10</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>9</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>9</Month><Day>28</Day><Hour>22</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>9</Month><Day>28</Day><Hour>22</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>9</Month><Day>28</Day><Hour>0</Hour><Minute>24</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>9</Month><Day>27</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39334246</ArticleId><ArticleId IdType="pmc">PMC11438358</ArticleId><ArticleId IdType="doi">10.1186/s12916-024-03637-z</ArticleId><ArticleId IdType="pii">10.1186/s12916-024-03637-z</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Pizevska M, Kaeda J, Fritsche E, Elazaly H, Reinke P, Amini L. Advanced therapy medicinal products’ translation in europe: a developers’ perspective. Front Med (Lausanne). 2022;9:757647.10.3389/fmed.2022.757647</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8851388</ArticleId><ArticleId IdType="pubmed">35186986</ArticleId></ArticleIdList></Reference><Reference><Citation>National Health Surveillance Agency (Anvisa). It provides on the rules for conducting clinical trials with investigational Advanced Therapy Medicinal Products in Brazil and other provisions. 2021. http://antigo.anvisa.gov.br/documents/10181/6278627/RDC_506_2021_.pdf/e932e631-4054-4014-9ac99813474e44a4. Accessed 21 Dec 2023.</Citation></Reference><Reference><Citation>Gomes K, da Silva R, da Silva J, Bosio C, Novaes M. Post-marketing authorisation safety and efficacy surveillance of advanced therapy medicinal products in Brazil, the European Union, the United States and Japan. Cytotherapy. 2023;25(10):1113–23. 10.1016/j.jcyt.2023.06.005.</Citation><ArticleIdList><ArticleId IdType="pubmed">37436339</ArticleId></ArticleIdList></Reference><Reference><Citation>Trisha G. Hemophilia: after a setback, gene therapy progresses gingerly. Science. 2001;291:1692–7. 10.1126/science.291.5509.1692.</Citation><ArticleIdList><ArticleId IdType="pubmed">11253191</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu W, Wang Y, Tang Z, Gao Y, Huo Y. Regulatory oversight of cell-based therapy in China: government’s efforts in patient access and therapeutic innovation. Pharmacol Res. 2020;158:104889.</Citation><ArticleIdList><ArticleId IdType="pubmed">32428666</ArticleId></ArticleIdList></Reference><Reference><Citation>Gang W. Comparison of regulatory policies for cell and gene therapy products between China and America. Chin Food Drug Admin Mag. 2019;187(08):20–5. 10.3969/j.issn.1673-5390.2019.08.02.</Citation></Reference><Reference><Citation>Center for Biologics Evaluation and Research (CBER). Guidance for human somatic cell therapy and gene therapy. 1998. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-human-somatic-cell-therapy-and-gene-therapy. Accessed 18 Sept 2023.</Citation></Reference><Reference><Citation>Lyu M, Chen J, Peng Y, Han F, Gong L, Guo J, et al. The global patent landscape of mRNA for diagnosis and therapy. Nat Biotechnol. 2023;41(9):1193–9. 10.1038/s41587-023-01925-2.</Citation><ArticleIdList><ArticleId IdType="pubmed">37699990</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu W, Huo Y, Ding X, Zhou Y, Gu S, Gao Y. Identification of the risks in CAR T-celtherapy clinical trials in China: a Delphi study. Ther Adv Med Oncol. 2020;12:1–12. 10.1177/1758835920966574.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7580145</ArticleId><ArticleId IdType="pubmed">33149770</ArticleId></ArticleIdList></Reference><Reference><Citation>Goula A, Gkioka V, Michalopoulos E, Katsimpoulas M, Noutsias M, Sarri EF, et al. Advanced therapy medicinal products challenges and perspectives in regenerative medicine. J Clin Med Res. 2020;12(12):780–6. 10.14740/jocmr3964.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7781285</ArticleId><ArticleId IdType="pubmed">33447311</ArticleId></ArticleIdList></Reference><Reference><Citation>European Medicines Agency (EMA). CHMP: agendas, minutes and highlights. https://www.ema.europa.eu/en/committees/chmp/chmp-agendas-minutes-highlights. Accessed 7 Sept 2022.</Citation></Reference><Reference><Citation>U.S. Food &amp; Drug Administration (FDA). Approved cellular and gene therapy products. https://www.fda.gov/vaccines-blood-biologics/cellular-gene-therapy-products/approved-cellular-and-gene-therapy-products. Accessed 10 Sept 2022.</Citation></Reference><Reference><Citation>Pharmaceuticals and Medical Device Agency (PMDA). Regenerative medical products. https://www.pmda.go.jp/english/review-services/reviews/approved-information/0003.html. Accessed 7 Sept 2022.</Citation></Reference><Reference><Citation>Ministry of Food and Drug Safety (MFDS). 2022 Drug Approval Report. 2023. https://www.mfds.go.kr/eng/brd/m_19/view.do?seq=70438. Accessed 28 Dec 2023.</Citation></Reference><Reference><Citation>The American Society of Gene&amp;Cell Therapy (ASGCT). Gene, cell &amp; RNA therapy landscape report. 2023. https://asgct.org/global/documents/asgct-citeline-q3-2023-report.aspx. Accessed 28 Dec 2023.</Citation></Reference><Reference><Citation>U.S. Food &amp; Drug Administration (FDA). Postmarket requirements and commitments. https://www.accessdata.fda.gov/scripts/cder/pmc/index.cfm. Accessed 2 Mar 2023.</Citation></Reference><Reference><Citation>European Medicines Agency (EMA). How EMA evaluates medicines for human use. 2022. https://www.ema.europa.eu/en/about-us/what-we-do/authorisation-medicines/how-ema-evaluates-medicines-human-use. Accessed 9 Mar 2022.</Citation></Reference><Reference><Citation>European Medicines Agency (EMA). Support for early access. 2016. https://www.ema.europa.eu/en/human-regulatory-overview/support-early-access. Accessed 12 Dec 2022.</Citation></Reference><Reference><Citation>European Medicines Agency (EMA). PRIME: priority medicines. 2016. https://www.ema.europa.eu/en/human-regulatory-overview/research-and-development/prime-priority-medicines. Accessed 12 Dec 2022.</Citation></Reference><Reference><Citation>European Medicines Agency (EMA). Pharmacovigilance Risk Assessment Committee (PRAC). 2022. https://www.ema.europa.eu/en/committees/pharmacovigilance-risk-assessment-committee-prac. Accessed 23 Jan 2022.</Citation></Reference><Reference><Citation>European Medicines Agency (EMA). Guideline on safety and efficacy follow-up-risk management of advanced therapy medicinal products. 2007. https://www.ema.europa.eu/en/guideline-safety-efficacy-follow-risk-management-advanced-therapy-medicinal-products-scientific. Accessed 10 Dec 2020.</Citation></Reference><Reference><Citation>European Medicines Agency (EMA). Guideline on safety and efficacy follow-up and risk management of advanced therapy medicinal products draft. 2018. https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-safety-efficacy-follow-risk-management-advanced-therapy-medicinal-products-revision_en.pdf. Accessed 9 Aug 2022.</Citation></Reference><Reference><Citation>European Medicines Agency (EMA). Clinical trials in small populations. 2006. https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-clinical-trials-small-populations_en.pdf. Accessed 7 Sept 2022.</Citation></Reference><Reference><Citation>Ma Y, Wu H, Zhang L, Song H, Huang J, Yang T. Analysis and reflection on the regulatory system for post-marketing safety research of EU drugs. Drug Eval Res. 2021;44(06):1141–8. 10.7501/j.issn.1674-6376.2021.06.002.</Citation></Reference><Reference><Citation>European Medicines Agency (EMA). Guideline on scientific requirements for the environmental risk assessment of gene therapy medicinal products. 2008. https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-scientific-requirements-environmental-risk-assessment-gene-therapy-medicinal-products_en.pdf. Accessed 15 Dec 2022.</Citation></Reference><Reference><Citation>European Medicines Agency (EMA). Reflection paper on management of clinical risks deriving from insertional mutagenesis. 2013. https://www.ema.europa.eu/en/documents/scientific-guideline/reflection-paper-management-clinical-risks-deriving-insertional-mutagenesis_en.pdf. Accessed 5 Dec 2022.</Citation><ArticleIdList><ArticleId IdType="pubmed">23862696</ArticleId></ArticleIdList></Reference><Reference><Citation>European Medicines Agency (EMA). Guideline on follow-up of patients administered with gene therapy medicinal products. https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-follow-patients-administered-gene-therapy-medicinal-products_en.pdf. Accessed 6 Dec 2022.</Citation></Reference><Reference><Citation>European Medicines Agency (EMA). Guideline on potency testing of cell-based immunotherapy medicinal products for the treatment of cancer. https://www.ema.europa.eu/en/potency-testing-cell-based-immunotherapy-medicinal-products-treatment-cancer-scientific-guideline. Accessed 1 Nov 2022.</Citation></Reference><Reference><Citation>European Medicines Agency (EMA). Guideline on Good Pharmacovigilance Practices (GVP) Module VIII – Post-authorisation Safety Studies (Rev 3). 2017. https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-good-pharmacovigilance-practices-gvp-module-viii-post-authorisation-safety-studies-rev-3_en.pdf. Accessed 27 July 2022.</Citation></Reference><Reference><Citation>European Medicines Agency (EMA). Guideline on Good Pharmacovigilance Practices (GVP) Module V – Risk Management Systems (Rev 2) 2017. https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-good-pharmacovigilance-practices-module-v-risk-management-systems-rev-2_en.pdf. Accessed 12 Dec 2021.</Citation></Reference><Reference><Citation>European Medicines Agency (EMA). Guideline on Good Pharmacovigilance Practices (GVP) Module XVI Risk Minimisation Measures: Selection of Tools and Effectiveness Indicators (Rev 2). 2017. https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-goodpharmacovigilance-practices-module-xvi-risk-minimisation-measures-selection-tools_en-3.pdf. Accessed 28 Mar 2017.
</Citation></Reference><Reference><Citation>European Medicines Agency (EMA). Draft guideline on Core SmPC, labelling and package leaflet for advanced therapy medicinal products (ATMPs) containing genetically modified cells. 2021. https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-core-smpc-labelling-package-leaflet-advanced-therapy-medicinal-products-atmps_en.pdf. Accessed 8 Aug 2022.</Citation></Reference><Reference><Citation>European Medicines Agency (EMA). Risk management plans (RMP) in post-authorisation phase: questions and answers. 2020. https://www.ema.europa.eu/en/human-regulatory/post-authorisation/pharmacovigilance/risk-management-plans-rmp-post-authorisation-phase-questions-answers. Accessed 1 March 2022.</Citation></Reference><Reference><Citation>European Medicines Agency (EMA). European Medicines Agency post-authorisation procedural advice for users of the centralised procedure. 2022. https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/european-medicines-agency-post-authorisation-procedural-advice-users-centralised-procedure_en.pdf. Accessed 21 Dec 2022.</Citation></Reference><Reference><Citation>European Medicines Agency (EMA). Guidance on the format of the risk management plan (RMP) in the EU–in integrated format. 2018. https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/guidance-format-risk-management-plan-rmp-eu-integrated-format-rev-201_en.pdf. Accessed 13 Dec 2021.</Citation></Reference><Reference><Citation>European Medicines Agency (EMA). Questions and answers on the risk management plan (RMP) summary. 2017. https://www.ema.europa.eu/en/documents/other/questions-answers-risk-management-plan-rmp-summary_en.pdf. Accessed 30 Mar 2017.</Citation></Reference><Reference><Citation>European Medicines Agency (EMA). Anonymisation of protected personal data and assessment of commercially confidential information during the preparation of risk management plans (main body and annexes 4 and 6) general guidance. 2022. https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/guidance-anonymisation-protected-personal-data-and-assessment-commercially-confidential-information-during-preparation-rmps-main-body-and-annexes-4-and-6_en.pdf. Accessed 15 Oct 2022.</Citation></Reference><Reference><Citation>European Medicines Agency (EMA). Guideline on Good Pharmacovigilance Practices (GVP) - Module VI – Collection, Management and Submission of Reports of Suspected Adverse Reactions to Medicinal Products (Rev. 2) 2017. https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/guideline-good-pharmacovigilance-practices-gvp-module-vi-collection-management-and-submission-reports-suspected-adverse-reactions-medicinal-products-rev-2_en.pdf. Accessed 25 Dec 2022.</Citation></Reference><Reference><Citation>european Medicines Agency (EMA). Guideline on Good Pharmacovigilance Practices (GVP) Module IX – Signal Management (Rev 1). 2017. https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-good-pharmacovigilance-practices-gvp-module-ix-signal-management-rev-1_en.pdf. Accessed 25 Dec 2022.
</Citation></Reference><Reference><Citation>European Medicines Agency (EMA). Guideline on Good Pharmacovigilance Practices (GVP) Module X – Additional Monitoring. 2013. https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-good-pharmacovigilance-practices-module-x-additional-monitoring_en.pdf. Accessed 8 Aug 2022.
</Citation></Reference><Reference><Citation>European Medicines Agency (EMA). Guideline on Good Pharmacovigilance Practices (GVP) Module XV – Safety Communication (Rev 1). https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-good-pharmacovigilance-practices-module-xv-safety-communication-rev-1_en.pdf. Accessed 25 Dec 2022.
</Citation></Reference><Reference><Citation>European Medicines Agency (EMA). Guidance for the format and content of the final study report of non-interventional post-authorisation safety studies. 2013. https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/guidance-format-content-final-study-report-non-interventional-post-authorisation-safety-studies_en.pdf. Accessed 28 July 2022.</Citation></Reference><Reference><Citation>European Medicines Agency (EMA). Hemgenix. 2023. https://www.ema.europa.eu/en/medicines/human/EPAR/hemgenix. Accessed 9 Sept 2023.</Citation></Reference><Reference><Citation>Holm J, Ruppert J, Ramsden S. Impact of changing regulations and the dynamic nature of european risk management plans for human medicines on the lifecycle of safety concerns. Pharmaceut Med. 2022;36(1):33–46. 10.1007/s40290-021-00414-8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8817998</ArticleId><ArticleId IdType="pubmed">35099785</ArticleId></ArticleIdList></Reference><Reference><Citation>Santoro A, Genov G, Spooner A, Raine J, Arlett P. Promoting and protecting public health: how the European Union pharmacovigilance system works. Drug Saf. 2017;40(10):855–69. 10.1007/s40264-017-0572-8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5606958</ArticleId><ArticleId IdType="pubmed">28735357</ArticleId></ArticleIdList></Reference><Reference><Citation>European Medicines Agency (EMA). Periodic safety update reports (PSURs). 2022. https://www.ema.europa.eu/en/human-regulatory/post-authorisation/pharmacovigilance/periodicsafety-update-reports-psurs. Accessed 12 Sept 2022.</Citation></Reference><Reference><Citation>Francisca RDC, Baba E, Hoeve CE, Zomerdijk IM, Sturkenboom M, Straus S. Introduction or discontinuation of additional risk minimisation measures during the life cycle of medicines in Europe. Drug Saf. 2021;44(1):63–72. 10.1007/s40264-020-00993-6.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7813721</ArticleId><ArticleId IdType="pubmed">33000427</ArticleId></ArticleIdList></Reference><Reference><Citation>European Medicines Agency (EMA). Scientific guidance on post-authorisation efficacy studies. 2016. https://www.ema.europa.eu/en/documents/scientific-guideline/scientific-guidance-post-authorisation-efficacy-studies-first-version_en.pdf. Accessed 27 Aug 2022.</Citation></Reference><Reference><Citation>U.S. Food &amp; Drug Administration (FDA). Risk evaluation and mitigation strategies | REMS. 2021. https://www.fda.gov/drugs/drug-safety-and-availability/risk-evaluation-and-mitigation-strategies-rems. Accessed 17 Dec 2021.</Citation></Reference><Reference><Citation>U.S. Food &amp; Drug Administration (FDA). Postmarketing requirements and commitments: introduction. 2016. https://www.fda.gov/drugs/guidance-compliance-regulatory-information/postmarket-requirements-and-commitments. Accessed 22 Feb 2022.</Citation></Reference><Reference><Citation>Ministry of Food and Drug Safety (MFDS). Guideline on re-examination affairs of new drugs etc. 2021. https://www.mfds.go.kr/docviewer/skin/doc.html?fn=20230327042331364.pdf&amp;rs=/docviewer/result/eng0003/71532/1/202312. Accessed 4 Dec 2022.</Citation></Reference><Reference><Citation>Kondo H, Masamune K. Effectiveness of drug postmarketing all-case surveillance as a safety measure in Japan. Ther Adv Drug Saf. 2021;12:20420986211065216. 10.1177/20420986211065215.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8689626</ArticleId><ArticleId IdType="pubmed">34987750</ArticleId></ArticleIdList></Reference><Reference><Citation>Ministry of Food and Drug Safety (MFDS). Regulation on the execution of re-evaluation of pharmaceuticals. 2022. https://www.mfds.go.kr/eng/brd/m_18/view.do?seq=71508&amp;srchFr=&amp;srchTo=&amp;srchWord=&amp;srchTp=7&amp;itm_seq_1=0&amp;itm_seq_2=0&amp;multi_itm_seq=0&amp;company_cd=&amp;company_nm=&amp;page=3. Accessed 25 Jan 2022.</Citation></Reference><Reference><Citation>European Medicines Agency (EMA). Post-authorisation Safety Studies (PASS). https://www.ema.europa.eu/en/human-regulatory-overview/post-authorisation/pharmacovigilance-post-authorisation/post-authorisation-safety-studies-pass. Accessed 4 Dec 2023.</Citation></Reference><Reference><Citation>European Medicines Agency (EMA). Guidance for the format and content of the protocol of non-interventional post-authorisation safety studies. 2012. https://www.ema.europa.eu/en/documents/other/guidance-format-content-protocol-non-interventional-post-authorisation-safety-studies_en.pdf. Accessed 12 Aug 2022.</Citation></Reference><Reference><Citation>European Medicines Agency (EMA). Guidance for the format and content of the final study report of non-interventional postauthorisation safety studies. 2013. https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/guidance-formatcontent-final-study-report-non-interventional-post-authorisation-safety-studies_en.pdf. Accessed 12 Oct 2022.
</Citation></Reference><Reference><Citation>European Medicines Agency (EMA). &lt;PRAC&gt;&lt;Rapporteur&gt;&lt;preliminary&gt;&lt;updated&gt; non-interventional imposed PASS final study report &lt;and RMP&gt; assessment report. 2015. https://www.ema.europa.eu/en/documents/template-form/template-prac-assessment-report-non-interventional-imposed-pass-final-study-report_en.pdf. Accessed 9 Sept 2022.</Citation></Reference><Reference><Citation>U.S. Food &amp; Drug Administration (FDA). Human cells, tissues, and cellular and tissue-based products, 21 CFR 1271. 2020. https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm? CFRPart=1271&amp;showFR=1. Accessed 30 Dec 2020.</Citation></Reference><Reference><Citation>U.S. Food &amp; Drug Administration (FDA). What is gene therapy? 2018. https://www.fda.gov/vaccines-blood-biologics/cellular-gene-therapy-products/what-gene-therapy. Accessed 3 Dec 2020.</Citation></Reference><Reference><Citation>U.S. Food &amp; Drug Administration (FDA). Guidance for industry: expedited programs for serious conditions--Drugs and Biologics. 2014. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/expedited-programs-serious-conditions-drugs-and-biologics. Accessed 7 Aug 2022.</Citation></Reference><Reference><Citation>U.S. Food &amp; Drug Administration (FDA). Expedited programs for regenerative medicine therapies for serious conditions guidance for industry. 2019. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/expedited-programs-regenerative-medicine-therapies-serious-conditions. Accessed 16 Sept 2022.</Citation></Reference><Reference><Citation>Hurley EA, Hull D, Shriver SP. The next phase of human gene-therapy oversight. N Engl J Med. 2019;380(4):401–2. 10.1056/NEJMc1815048.</Citation><ArticleIdList><ArticleId IdType="pubmed">30681782</ArticleId></ArticleIdList></Reference><Reference><Citation>Gene Therapy Net. Gene therapy legislation in the US. 2021. http://www.genetherapynet.com/united-states-of-america.html. Accessed 12 Jan 2021.</Citation></Reference><Reference><Citation>U.S. Health &amp; Human Services (HHS). Register IRBs &amp; Obtain FWAs. 2021. https://www.hhs.gov/ohrp/register-irbs-and-obtain-fwas/index.html. Accessed 10 Jan 2021.</Citation></Reference><Reference><Citation>U.S. Food &amp; Drug Administration (FDA). Cellular &amp; gene therapy guidances. 2021. https://www.fda.gov/vaccines-blood-biologics/biologics-guidances/cellular-gene-therapy-guidances Accessed 10 Sept 2023.</Citation></Reference><Reference><Citation>U.S. Food &amp; Drug Administration (FDA). Guidance for industry: considerations for the design of early-phase clinical trials of cellular and gene therapy products. 2015. https://www.fda.gov/media/106369/download. Accessed 4 Dec 2020.</Citation></Reference><Reference><Citation>U.S. Food &amp; Drug Administration (FDA). FDA’s role in managing medication risks. https://www.fda.gov/drugs/risk-evaluation-and-mitigation-strategies-rems/fdas-role-managingmedication-risks. Accessed 17 Sept 2022.</Citation></Reference><Reference><Citation>U.S. Food &amp; Drug Administration (FDA). Guidance for industry: long term follow-up after administration of human gene therapy products. 2020. https://www.fda.gov/media/113768/download. Accessed 26 Dec 2020.</Citation></Reference><Reference><Citation>U.S. Food &amp; Drug Administration (FDA). Guidance for industry and health: testing of retroviral vector-based human gene therapy products for replication competent retrovirus during product manufacture and patient follow-up. 2020. https://www.fda.gov/media/113790/download. Accessed 13 May 2022.</Citation></Reference><Reference><Citation>U.S. Food &amp; Drug Administration (FDA). Guidance for industry: post-marketing studies and clinical trials —implementation of Section 505(o)(3) of the Federal Food, Drug, and Cosmetic Act. 2011. https://www.fda.gov/media/131980/download. Accessed 1 Sept. 2022.</Citation></Reference><Reference><Citation>U.S. Food &amp; Drug Administration (FDA). Draft guidance: post-marketing studies and clinical trials—implementation of Section 505(o)(3) of the Federal Food, Drug, and Cosmetic Act Guidance for Industry. 2019. https://www.fda.gov/media/148646/download. Accessed 1 Sept. 2022.</Citation></Reference><Reference><Citation>U.S. Food &amp; Drug Administration (FDA). What’s in a REMS? 2018. https://www.fda.gov/drugs/risk-evaluation-and-mitigation-strategies-rems/whats-rems. Accessed 1 Sept. 2022.</Citation></Reference><Reference><Citation>U.S. Food &amp; Drug Administration (FDA). REMS: FDA’s application of statutory factors in determining when a rems is necessary guidance for industry. 2019. https://www.fda.gov/media/100307/download. Accessed 8 Oct. 2022.</Citation></Reference><Reference><Citation>U.S. Food &amp; Drug Administration (FDA). Use of a Drug Master File for shared system REMS submissions guidance for industry draft guidance. 2017. https://www.fda.gov/media/109124/download. Accessed 20 Oct. 2022.</Citation></Reference><Reference><Citation>U.S. Food &amp; Drug Administration (FDA). Medication guides — distribution requirements and inclusion in risk evaluation and mitigation strategies (REMS). 2011. https://www.fda.gov/media/79776/download. Accessed 11 Oct. 2022.</Citation></Reference><Reference><Citation>U.S. Food &amp; Drug Administration (FDA). Format and content of a REMS document guidance for industry. 2023. https://www.fda.gov/media/79776/download. Accessed 1 Feb. 2023.</Citation></Reference><Reference><Citation>U.S. Food &amp; Drug Administration (FDA). Providing regulatory submissions in electronic format — content of the risk evaluation and mitigation strategies document using structured product labeling guidance for industry. 2020. https://www.fda.gov/media/107302/download. Accessed 5 Mar. 2022.</Citation></Reference><Reference><Citation>U.S. Food &amp; Drug Administration (FDA). Risk evaluation and mitigation strategies: modifications and revisions guidance for industry. 2020. https://www.fda.gov/media/128651/download. Accessed 5 Mar 2022.</Citation></Reference><Reference><Citation>U.S. Food &amp; Drug Administration (FDA). Policy for certain REMS requirements during the COVID-19 public health emergency guidance for industry and health care professionals. 2020. https://www.fda.gov/media/136317/download. Accessed 5 Mar 2022.</Citation></Reference><Reference><Citation>U.S. Food &amp; Drug Administration (FDA). REMS document technical conformance guide. 2023. https://www.fda.gov/media/164344/download. Accessed 1 Feb 2023.</Citation></Reference><Reference><Citation>U.S. Food &amp; Drug Administration (FDA). Survey methodologies to assess REMS goals that relate to knowledge guidance for industry DRAFT GUIDANCE. 2019. https://www.fda.gov/media/119789/download. Accessed 15 Nov 2022.</Citation></Reference><Reference><Citation>U.S. Food &amp; Drug Administration (FDA). Development of a shared system REMS guidance for industry DRAFT GUIDANCE. 2018. https://www.fda.gov/media/113869/download. Accessed 23 Dec 2022.
</Citation></Reference><Reference><Citation>U.S. Food &amp; Drug Administration (FDA). REMS assessment: planning and reporting guidance for industry DRAFT GUIDANCE. 2019. https://www.fda.gov/media/119790/download. Accessed 27 Dec 2022.
</Citation></Reference><Reference><Citation>The International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH). Periodic benefit-risk evaluation report. 2012. https://database.ich.org/sites/default/files/E2C_R2_Guideline.pdf. Accessed 17 Sept 2022.</Citation></Reference><Reference><Citation>Chen J, Yu Z. Research on the safety summary report system after foreign listing and its enlightenment for China. Modern Commercial Industry. 2021;42(11):51–3. 10.19311/j.cnki.1672-3198.2021.11.026.</Citation></Reference><Reference><Citation>U.S. Food &amp; Drug Administration (FDA). Providing postmarket periodic safety reports in the ICH E2C(R2) format (Periodic Benefit-Risk Evaluation Report). 2016. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/providing-postmarket-periodic-safety-reports-ich-e2cr2-format-periodic-benefit-risk-evaluation. Accessed 5 Jan 2024.</Citation></Reference><Reference><Citation>U.S. Food &amp; Drug Administration (FDA). FDA investigating serious risk of T-cell malignancy following BCMA-directed or CD19-directed autologous chimeric antigen receptor (CAR) T cell immunotherapies. 2023. https://www.fda.gov/vaccines-blood-biologics/safety-availability-biologics/fda-investigating-serious-risk-t-cell-malignancy-following-bcma-directed-or-cd19-directed-autologous. Accessed 3 Dec 2023.</Citation></Reference><Reference><Citation>Konishi A, Sakushima K, Isobe S, Sato D. First approval of regenerative medical products under the PMD act in Japan. Cell Stem Cell. 2016;18(4):434–5. 10.1016/j.stem.2016.03.011.</Citation><ArticleIdList><ArticleId IdType="pubmed">27058934</ArticleId></ArticleIdList></Reference><Reference><Citation>Pharmaceuticals and Medical Device Agency (PMDA). Services of PMDA. 2022. https://www.pmda.go.jp/english/about-pmda/outline/0006.html. Accessed 8 Oct 2022.</Citation></Reference><Reference><Citation>Pharmaceuticals and Medical Device Agency (PMDA). SATO D. ACTO Satellite symposium - Japanese regulation of regenerative medicine. 2014. https://www.pmda.go.jp/files/000199507.pdf. Accessed 9 Dec 2022.</Citation></Reference><Reference><Citation>Diao Y, Liang Y. Management of cell therapy products in Japan and its implications for China. Prog Pharm Sci. 2019;43(12):908–13.</Citation></Reference><Reference><Citation>Ministry of Health LaWoJM. Strategy of SAKIGAKE. https://www.mhlw.go.jp/english/policy/health-medical/pharmaceuticals/140729-01.html. Accessed 20 Oct 2022.</Citation></Reference><Reference><Citation>Pharmaceuticals and Medical Device Agency (PMDA). Regulatory update from MHLW/PMDA. 2017. https://www.pmda.go.jp/files/000221880.pdf. Accessed 22 Oct 2022.</Citation></Reference><Reference><Citation>Azuma K. Regulatory landscape of regenerative medicine in Japan. Current Stem Cell Reports. 2015;1(2):118–28. 10.1007/s40778-015-0012-6.</Citation></Reference><Reference><Citation>Pharmaceuticals and Medical Device Agency (PMDA). Procedures for developing post-marketing study plan. 2018. https://www.pmda.go.jp/files/000226080.pdf. Accessed 9 Feb 2024.</Citation></Reference><Reference><Citation>Pharmaceuticals and Medical Device Agency (PMDA). Risk management plan guidance. 2012. https://www.pmda.go.jp/files/000153333.pdf. Accessed 9 Dec 2023.</Citation></Reference><Reference><Citation>Pharmaceuticals and Medical Device Agency (PMDA). Implementation methods, etc. of early post-marketing phase vigilance for prescription drugs. 2006. https://www.pmda.go.jp/files/000209204.pdf. Accessed 9 Feb 2024.</Citation></Reference><Reference><Citation>Pharmaceuticals and Medical Device Agency (PMDA). Risk management plan (RMP). https://www.pmda.go.jp/english/safety/info-services/drugs/rmp/0001.html. Accessed 29 Dec 2022.</Citation></Reference><Reference><Citation>TAWARAGI T. New streams of risk management. 2015. http://www.pmda.go.jp/files/000205832.pdf. Accessed 12 Oct 2022.</Citation></Reference><Reference><Citation>Ministry of Food and Drug Safety (MFDS). Biological products. 2023. https://www.mfds.go.kr/eng/wpge/m_22/de011012l001.do. Accessed 12 Sept 2023.</Citation></Reference><Reference><Citation>Ministry of Food and Drug Safety (MFDS). Pharmaceutical Affairs Act. 2019. https://www.mfds.go.kr/docviewer/skin/doc.html?fn=20211013112528933.pdf&amp;rs=/docviewer/result/eng0003/71500/1/202312. Accessed 24 Oct 2022.</Citation></Reference><Reference><Citation>Choi M, Han E, Lee S, Kim T, Shin W. Regulatory oversight of gene therapy and cell therapy products in Korea. Regulatory Aspects Gene Therapy Cell Therapy Products. Advances in Experimental Medicine and Biology2015. p. 163–179.</Citation><ArticleIdList><ArticleId IdType="pubmed">26374218</ArticleId></ArticleIdList></Reference><Reference><Citation>E H, Won S. Regulation of cell therapy products in Korea. ISBT Science Series. 2015; 10(Suppl. 1):129–133. 10.1111/voxs.12158.</Citation></Reference><Reference><Citation>Zhang Y, Jiang Y. Introduction and Insights into the Korean Pharmacovigilance System. Chinese J Pharmacovigilance. 2022;19(10):1082–6. 10.19803/j.1672-8629.20210331.</Citation></Reference><Reference><Citation>Ministry of Food and Drug Safety (MFDS). Standard for re-examination of new drugs. 2022. https://www.mfds.go.kr/eng/brd/m_18/view.do?seq=71517&amp;srchFr=&amp;srchTo=&amp;srchWord=&amp;srchTp=7&amp;itm_seq_1=0&amp;itm_seq_2=0&amp;multi_itm_seq=0&amp;company_cd=&amp;company_nm=&amp;page=2. Accessed 9 Feb 2022.</Citation></Reference><Reference><Citation>Ministry of Food and Drug Safety (MFDS). Regulation for pharmaceutical approvals, notifications and reviews. 2021. https://www.mfds.go.kr/docviewer/skin/doc.html?fn=20230327035644903.pdf&amp;rs=/docviewer/result/eng0003/71524/1/202312. Accessed 4 Oct 2022.
</Citation></Reference><Reference><Citation>Ministry of Food and Drug Safety (MFDS). Regulation on safety information control of medicinal products. 2016. https://www.mfds.go.kr/eng/brd/m_27/view.do?seq=70881&amp;srchFr=&amp;srchTo=&amp;srchWord=&amp;srchTp=&amp;itm_seq_1=0&amp;itm_seq_2=0&amp;multi_itm_seq=0&amp;company_cd=&amp;company_nm=&amp;page=2. Accessed 26 Sept 2021.
</Citation></Reference><Reference><Citation>Ministry of Food and Drug Safety (MFDS). Enforcement Decree of the Pharmaceutical Affairs Act. 2021. https://www.mfds.go.kr/eng/brd/m_18/view.do?seq=71501&amp;srchFr=&amp;srchTo=&amp;srchWord=&amp;srchTp=7&amp;itm_seq_1=0&amp;itm_seq_2=0&amp;multi_itm_seq=0&amp;company_cd=&amp;company_nm=&amp;page=3. Accessed 13 Oct 2021.
</Citation></Reference><Reference><Citation>National Medical Products Administration (NMPA). Main responsibilities of the National Drug Administration. 2022. https://www.nmpa.gov.cn/jggk/jgzhn/zhyzhz/index.html. Accessed 15 Nov 2022.</Citation></Reference><Reference><Citation>CENTER FOR DRUG EVALUATION (CDE). Role of the center. https://www.cde.org.cn/main/jgzn/contentpage/fc528384dbd9f6691ff56f7e1167b4ad. Accessed 25 Sept 2022.</Citation></Reference><Reference><Citation>State Adminitration for Market Regulation. Measures for the administration of drug registration. 2020. https://www.samr.gov.cn/zw/zfxxgk/fdzdgknr/fgs/art/2023/art_3275cb2a929d4c34ac8c0421b2a9c257.html. Accessed 9 Feb 2023.</Citation></Reference><Reference><Citation>Lu J, Xu L, Wei W, He W. Advanced therapy medicinal products in China: regulation and development. MedComm (2020). 2023; 4(3):e251. 10.1002/mco2.251.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10133728</ArticleId><ArticleId IdType="pubmed">37125239</ArticleId></ArticleIdList></Reference><Reference><Citation>National medical Products Administration (NMPA). Procedures for review and approval of applications for conditional marketing authorization of medicinal products (Trial Implementation) (draft for soliciting comments). 2023. https://www.nmpa.gov.cn/xxgk/zhqyj/zhqyjyp/20230825104212129.html. Accessed 15 Feb 2024.</Citation></Reference><Reference><Citation>National Medical Products Administration (NMPA). Drug Administration Law. 2019. https://www.nmpa.gov.cn/xxgk/fgwj/flxzhfg/20190827083801685.html. Accessed 27 Aug 2022.</Citation></Reference><Reference><Citation>National Medical Products Administration (NMPA). Announcement of the State Food and Drug Administration on the issuance of the “Quality Management Standards for Pharmacovigilance"”(No. 65 of 2021). 2021. https://www.nmpa.gov.cn/yaopin/ypfgwj/ypfggzwj/20210513151827179.html. Accessed 13 May 2021.</Citation></Reference><Reference><Citation>Center for Drug Evaluation (CDE). Technical guidelines for long-term follow-up clinical studies of gene therapy products. 2021. https://www.cde.org.cn/main/news/viewInfoCommon/c9de887410ddcc291ce5a1c039a241c6. Accessed 3 Dec 2021.</Citation></Reference><Reference><Citation>Center for Drug Evaluation (CDE). Technical guidelines for clinical risk management plan of chimeric antigen receptor T cell (CAR-T) Therapeutic Products. 2022. https://www.cde.org.cn/main/news/viewInfoCommon/574e71202540d2b38cf34dfeb5673a86. Accessed 29 Jan 2022.</Citation></Reference><Reference><Citation>Center for Drug Evaluation (CDE). Guidance for writing a clinical risk management plan (for Trial Implementation). 2022. https://www.cde.org.cn/main/news/viewInfoCommon/77e34e30c7141b2770ddd6f80e80f9ff. Accessed 6 Jan 2022.</Citation></Reference><Reference><Citation>National Medical Products Administration (NMPA). Guidelines for pharmacovigilance examination. 2022. https://www.nmpa.gov.cn/xxgk/fgwj/gzwj/gzwjyp/20220415102743184.html. Accessed 12 Sept 2023.</Citation></Reference><Reference><Citation>QVigilance. a guide to the US FDA safety requirements for pharmacovigilance. 2019. https://www.qvigilance.com/blog/usa-fda-safety-requirements-pharmacovigilance. Accessed 17 Feb 2024.</Citation></Reference><Reference><Citation>European Medicines Agency (EMA). Ebvallo. 2022. https://www.ema.europa.eu/en/medicines/human/EPAR/ebvallo. Accessed 9 Sept 2023.</Citation></Reference><Reference><Citation>European Medicines Agency (EMA). Breyanzi. 2022. https://www.ema.europa.eu/en/medicines/human/EPAR/breyanzi. Accessed 9 Sept 2023.
</Citation></Reference><Reference><Citation>European Medicines Agency (EMA). Roctavian. 2022. https://www.ema.europa.eu/en/medicines/human/EPAR/roctavian-0. Accessed 1 Feb 2023.
</Citation></Reference><Reference><Citation>European Medicines Agency (EMA). Upstaza. 2022. https://www.ema.europa.eu/en/medicines/human/EPAR/upstaza. Accessed 1 Feb 2023.
</Citation></Reference><Reference><Citation>European Medicines Agency (EMA). Carvykti. 2022. https://www.ema.europa.eu/en/medicines/human/EPAR/carvykti. Accessed 1 Feb 2023.
</Citation></Reference><Reference><Citation>European Medicines Agency (EMA). Abecma. 2021. https://www.ema.europa.eu/en/medicines/human/EPAR/abecma. Accessed 21 Dec 2022.
</Citation></Reference><Reference><Citation>European Medicines Agency (EMA). Skysona. 2021. https://www.ema.europa.eu/en/medicines/human/EPAR/skysona. Accessed 1 Mar 2023.
</Citation></Reference><Reference><Citation>European Medicines Agency (EMA). Libmeldy. 2020. https://www.ema.europa.eu/en/medicines/human/EPAR/libmeldy. Accessed 1 Feb 2023.
</Citation></Reference><Reference><Citation>European Medicines Agency (EMA). Tecartus. 2020. https://www.ema.europa.eu/en/medicines/human/EPAR/tecartus. Accessed 30 Jan 2023.
</Citation></Reference><Reference><Citation>European Medicines Agency (EMA). Zolgensma. 2020. https://www.ema.europa.eu/en/medicines/human/EPAR/zolgensma. Accessed 17 Feb 2023.
</Citation></Reference><Reference><Citation>European Medicines Agency (EMA). Zynteglo. 2019. https://www.ema.europa.eu/en/medicines/human/EPAR/zynteglo. Accessed 30 Nov 2022.
</Citation></Reference><Reference><Citation>European Medicines Agency (EMA). Luxturna. 2018. https://www.ema.europa.eu/en/medicines/human/EPAR/luxturna. Accessed 19 Aug 2022.
</Citation></Reference><Reference><Citation>European Medicines Agency (EMA). Yescarta. 2018. https://www.ema.europa.eu/en/medicines/human/EPAR/yescarta. Accessed 30 Jan 2023.
</Citation></Reference><Reference><Citation>European Medicines Agency (EMA). Kymriah. 2018. https://www.ema.europa.eu/en/medicines/human/EPAR/kymriah. Accessed 7 Nov 2022.
</Citation></Reference><Reference><Citation>European Medicines Agency (EMA). Alofisel. 2018. https://www.ema.europa.eu/en/medicines/human/EPAR/alofisel. Accessed 12 Jan 2023.
</Citation></Reference><Reference><Citation>European Medicines Agency (EMA). Spherox. 2017. https://www.ema.europa.eu/en/medicines/human/EPAR/spherox. Accessed 16 Jan 2023.
</Citation></Reference><Reference><Citation>European Medicines Agency (EMA). Strimvelis. 2016. https://www.ema.europa.eu/en/medicines/human/EPAR/strimvelis. Accessed 1 Aug 2022.
</Citation></Reference><Reference><Citation>European Medicines Agency (EMA). Zalmoxis. 2016. https://www.ema.europa.eu/en/medicines/human/EPAR/zalmoxis. Accessed 14 Feb 2020.
</Citation></Reference><Reference><Citation>European Medicines Agency (EMA). Imlygic. 2015. https://www.ema.europa.eu/en/medicines/human/EPAR/imlygic. Accessed 15 Dec 2022.
</Citation></Reference><Reference><Citation>European Medicines Agency (EMA). Holoclar. 2015. https://www.ema.europa.eu/en/medicines/human/EPAR/holoclar. Accessed 6 Jan 2022.
</Citation></Reference><Reference><Citation>European Medicines Agency (EMA). Provenge. 2013. https://www.ema.europa.eu/en/medicines/human/EPAR/provenge. Accessed 19 May 2015.
</Citation></Reference><Reference><Citation>European Medicines Agency (EMA). Maci. 2013. https://www.ema.europa.eu/en/medicines/human/EPAR/maci. Accessed 5 July 2018.
</Citation></Reference><Reference><Citation>European Medicines Agency (EMA). Glybera. 2012. https://www.ema.europa.eu/en/medicines/human/EPAR/glybera. Accessed 30 Oct 2017.
</Citation></Reference><Reference><Citation>European Medicines Agency (EMA). Chondrocelect. 2009. https://www.ema.europa.eu/en/medicines/human/EPAR/chondrocelect. Accessed 28 May 2019.
</Citation></Reference><Reference><Citation>European Medicines Agency (EMA). Casgevy. 2023. https://www.ema.europa.eu/en/documents/assessment-report/casgevy-epar-public-assessment-report_en.pdf. Accessed 21 June 2024.</Citation></Reference><Reference><Citation>US Food and Drug Administration (FDA). LANTIDRA. 2023. https://www.fda.gov/vaccines-blood-biologics/lantidra. Accessed 10 Sept 2023.</Citation></Reference><Reference><Citation>US Food and Drug Administration (FDA). ROCTAVIAN. 2023. US Food and Drug Administration (FDA). Accessed 10 Sept 2023.</Citation></Reference><Reference><Citation>US Food and Drug Administration (FDA). ELEVIDYS. 2023. https://www.fda.gov/vaccines-blood-biologics/tissue-tissue-products/elevidys. Accessed 10 Sept 2023.</Citation></Reference><Reference><Citation>US Food and Drug Administration (FDA). VYJUVEK. 2023. https://www.fda.gov/vaccines-blood-biologics/vyjuvek. Accessed 10 Sept 2023.
</Citation></Reference><Reference><Citation>US Food and Drug Administration (FDA). ADSTILADRIN. 2022. https://www.fda.gov/vaccines-blood-biologics/cellular-gene-therapy-products/adstiladrin. Accessed 7 Jan 2023.
</Citation></Reference><Reference><Citation>US Food and Drug Administration (FDA). HEMGENIX. 2022. https://www.fda.gov/vaccines-blood-biologics/vaccines/hemgenix. Accessed 8 Sept 2023.
</Citation></Reference><Reference><Citation>US Food and Drug Administration (FDA). SKYSONA. 2022. https://www.fda.gov/vaccines-blood-biologics/skysona. Accessed 25 Oct 2022.
</Citation></Reference><Reference><Citation>US Food and Drug Administration (FDA). ZYNTEGLO. 2022. https://www.fda.gov/vaccines-blood-biologics/zynteglo. Accessed 7 Jan 2023.
</Citation></Reference><Reference><Citation>US Food and Drug Administration (FDA). CARVYKTI. 2022. https://www.fda.gov/vaccines-blood-biologics/carvykti. Accessed 7 Jan 2023.
</Citation></Reference><Reference><Citation>US Food and Drug Administration (FDA). RETHYMIC. 2021. https://www.fda.gov/vaccines-blood-biologics/rethymic. Accessed 4 Nov 2021.
</Citation></Reference><Reference><Citation>US Food and Drug Administration (FDA). STRATAGRAFT. 2021. https://www.fda.gov/vaccines-blood-biologics/stratagraft. Accessed 13 July 2021.
</Citation></Reference><Reference><Citation>US Food and Drug Administration (FDA). ABECMA (idecabtagene vicleucel). 2021. https://www.fda.gov/vaccines-blood-biologics/abecma-idecabtagene-vicleucel. Accessed January 21, 2021.</Citation></Reference><Reference><Citation>US Food and Drug Administration (FDA). BREYANZI (lisocabtagene maraleucel). 2021. https://www.fda.gov/vaccines-blood-biologics/cellular-gene-therapy-products/breyanzi-lisocabtagene-maraleucel. Accessed July 1, 2022.</Citation></Reference><Reference><Citation>US Food and Drug Administration (FDA). TECARTUS (brexucabtagene autoleucel). 2020. https://www.fda.gov/vaccines-blood-biologics/cellular-gene-therapy-products/tecartus-brexucabtagene-autoleucel. Accessed April 13, 2022.</Citation></Reference><Reference><Citation>US Food and Drug Administration (FDA). ZOLGENSMA. 2019. https://www.fda.gov/vaccines-blood-biologics/zolgensma. Accessed February 16, 2023.</Citation></Reference><Reference><Citation>US Food and Drug Administration (FDA). KYMRIAH (tisagenlecleucel). 2018. https://www.fda.gov/vaccines-blood-biologics/cellular-gene-therapy-products/kymriah-tisagenlecleucel. Accessed July 7, 2022.</Citation></Reference><Reference><Citation>US Food and Drug Administration (FDA). LUXTURNA. 2017. https://www.fda.gov/vaccines-blood-biologics/cellular-gene-therapy-products/luxturna. Accessed June 9, 2022.</Citation></Reference><Reference><Citation>US Food and Drug Administration (FDA). YESCARTA (axicabtagene ciloleucel). 2017. https://www.fda.gov/vaccines-blood-biologics/cellular-gene-therapy-products/yescarta-axicabtagene-ciloleucel. Accessed November 4, 2022.</Citation></Reference><Reference><Citation>US Food and Drug Administration (FDA). MACI (Autologous Cultured Chondrocytes on a Porcine Collagen Membrane). 2016. https://www.fda.gov/vaccines-blood-biologics/cellular-gene-therapy-products/maci-autologous-cultured-chondrocytes-porcine-collagen-membrane. Accessed June 30, 2021.</Citation></Reference><Reference><Citation>US Food and Drug Administration (FDA). IMLYGIC. 2015. https://www.fda.gov/vaccines-blood-biologics/cellular-gene-therapy-products/imlygic. Accessed February 15, 2023.</Citation></Reference><Reference><Citation>US Food and Drug Administration (FDA). GINTUIT (allogeneic cultured keratinocytes and fibroblasts in bovine collagen). 2012. https://www.fda.gov/vaccines-blood-biologics/cellular-gene-therapy-products/gintuit-allogeneic-cultured-keratinocytes-and-fibroblasts-bovine-collagen. Accessed 20 Feb 2018.</Citation></Reference><Reference><Citation>US Food and Drug Administration (FDA). PROVENGE (sipuleucel-T). 2010. https://www.fda.gov/vaccines-blood-biologics/cellular-gene-therapy-products/provenge-sipuleucel-t. Accessed 28 May 2019.
</Citation></Reference><Reference><Citation>US Food and Drug Administration (FDA). BEQVEZ. 2024. https://www.fda.gov/vaccines-blood-biologics/cellular-gene-therapy-products/beqvez. Accessed 21 June 2024.
</Citation></Reference><Reference><Citation>U.S. Food &amp; Drug Administration (FDA). LENMELDY. 2024. https://www.fda.gov/vaccines-blood-biologics/cellular-gene-therapy-products/lenmeldy. Accessed 21 June 2024.
</Citation></Reference><Reference><Citation>U.S. Food &amp; Drug Administration (FDA). AMTAGVI. 2024. https://www.fda.gov/vaccines-blood-biologics/approved-blood-products/amtagvi. Accessed 21 June 2024.
</Citation></Reference><Reference><Citation>U.S. Food &amp; Drug Administration (FDA). CASGEVY. 2023. https://www.fda.gov/vaccines-blood-biologics/casgevy. Accessed 21 June 2024.
</Citation></Reference><Reference><Citation>U.S. Food &amp; Drug Administration (FDA). LYFGENIA. 2023. https://www.fda.gov/vaccines-blood-biologics/lyfgenia. Accessed 21 June 2024.
</Citation></Reference><Reference><Citation>Pharmaceuticals and Medical Device Agency (PMDA). Vyznova. 2023. https://www.pmda.go.jp/files/000263641.pdf. Accessed 10 Sept 2023.
</Citation></Reference><Reference><Citation>Pharmaceuticals and Medical Device Agency (PMDA). JACEMIN. 2023. https://www.pmda.go.jp/files/000264109.pdf. Accessed 10 Sept 2023.
</Citation></Reference><Reference><Citation>Pharmaceuticals and Medical Device Agency (PMDA). Carvykti. 2022. https://www.pmda.go.jp/files/000252610.pdf. Accessed 3 Aug 2022.
</Citation></Reference><Reference><Citation>Pharmaceuticals and Medical Device Agency (PMDA). Abecma. 2021. https://www.pmda.go.jp/files/000250563.pdf. Accessed 6 Dec 2021.
</Citation></Reference><Reference><Citation>Pharmaceuticals and Medical Device Agency (PMDA). Sakracy. 2021. https://www.pmda.go.jp/files/000247920.pdf. Accessed 6 Dec 2021.
</Citation></Reference><Reference><Citation>Pharmaceuticals and Medical Device Agency (PMDA). Alofisel. 2021. https://www.pmda.go.jp/files/000246420.pdf. Accessed 6 Sept 2021.
</Citation></Reference><Reference><Citation>Pharmaceuticals and Medical Device Agency (PMDA). Delytact. 2021. https://www.pmda.go.jp/files/000242808.pdf. Accessed 24 May 2021.
</Citation></Reference><Reference><Citation>Pharmaceuticals and Medical Device Agency (PMDA). Ocural. 2021. https://www.pmda.go.jp/files/000246286.pdf. Accessed 24 May 2021.
</Citation></Reference><Reference><Citation>Pharmaceuticals and Medical Device Agency (PMDA). Breyanzi. 2021. https://www.pmda.go.jp/files/000243465.pdf. Accessed 5 Mar 2021.
</Citation></Reference><Reference><Citation>Pharmaceuticals and Medical Device Agency (PMDA). YESCARTA. 2021. https://www.pmda.go.jp/files/000243495.pdf. Accessed 3 Dec 2021.
</Citation></Reference><Reference><Citation>Pharmaceuticals and Medical Device Agency (PMDA). ZOLGENSMA. 2020. https://www.pmda.go.jp/files/000237139.pdf. Accessed 26 Feb 2020.
</Citation></Reference><Reference><Citation>Pharmaceuticals and Medical Device Agency (PMDA). Nepic. 2020. https://www.pmda.go.jp/files/000237511.pdf. Accessed 7 Feb 2022.
</Citation></Reference><Reference><Citation>Pharmaceuticals and Medical Device Agency (PMDA). Collategene. 2019. https://www.pmda.go.jp/files/000231386.pdf. Accessed 20 Feb 2019.
</Citation></Reference><Reference><Citation>Pharmaceuticals and Medical Device Agency (PMDA). Kymriah. 2018. https://www.pmda.go.jp/files/000231651.pdf. Accessed Feb 2019.
</Citation></Reference><Reference><Citation>Pharmaceuticals and Medical Device Agency (PMDA). Stemirac. 2018. https://www.pmda.go.jp/files/000231946.pdf. Accessed 21 Nov 2019.
</Citation></Reference><Reference><Citation>Pharmaceuticals and Medical Device Agency (PMDA). JACE. 2016. https://www.pmda.go.jp/files/000223079.pdf. Accessed 6 Aug 2022.
</Citation></Reference><Reference><Citation>Pharmaceuticals and Medical Device Agency (PMDA). HeartSheet. 2015. https://www.pmda.go.jp/files/000215222.pdf. Accessed 8 Sept 2022.
</Citation></Reference><Reference><Citation>Pharmaceuticals and Medical Device Agency (PMDA). Temcell. 2015. https://www.pmda.go.jp/files/000215658.pdf. Accessed 2 Sept 2022.
</Citation></Reference><Reference><Citation>Pharmaceuticals and Medical Device Agency (PMDA). JACC. 2012. https://www.pmda.go.jp/files/000229937.pdf. Accessed 6 Sept 2021.
</Citation></Reference></ReferenceList></PubmedData></PubmedArticle>